Nurix Therapeutics' stock surged 5.90% during intraday trading on Thursday, reflecting strong investor confidence in the biotechnology company.
The price increase follows a series of positive analyst actions, including price target raises and maintained buy ratings from multiple firms. H.C. Wainwright increased its target price to $32 from $31, Stifel raised its target to $35 from $33, and RBC lifted its target to $30 from $28, all while maintaining bullish ratings. Additionally, Wells Fargo maintained an Overweight rating and BTIG sustained its positive outlook with a $30 price target.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments